CNCR
Loncar Cancer Immunotherapy ETF [CNCR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CNCR Stock Summary
Top CNCR Correlated Resources
CNCR
Top 10 Correlated ETFs
CNCR
Top 10 Correlated Stocks
CNCR
In the News
CNCR Financial details
Company Rating
-
Market Cap
28.74M
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-9.09%
SMA50
-16.67%
SMA100
-33.33%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.22-17.96
52W High
-43.88%
52W Low
+6%
RSI
27
Rel Volume
0.09
Avg Volume
34.59K
Volume
2.97K
Perf Week
-10.51%
Perf Month
-24.64%
Perf Quarter
-34.3%
Perf Half Y
-36.7%
-
-
-
-
Beta
0.89
-
-
Volatility
0.4%, 0.76%
Prev Close
-3.34%
Price
9.54
Change
-4.5%
Company Profile
- Volume Average 34.59K
- Market Capitalization 28.74M
- Headquarters US
- IPO Date 2015-10-14
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.
